In a study of single‐agent enitociclib (VIP152), a CDK9 inhibitor, two of seven patients with high‐grade B‐cell lymphoma double‐hit with MYC and BCL2 rearrangements (HGBCL‐DH‐BCL2) achieved complete response (CR), both ongoing after 2.3 and 3.7 years of follow‐up.11, 12. This evidence concerns the gene BCL2 and B-cell non-Hodgkin lymphoma.